Grants for Special district governments - Food and Nutrition

The Rose Foundation for Communities and the Environment, in partnership with the Bay Foundation of Morro Bay, is offering a grant opportunity through the Central Coast Community-Based Water Quality Grants Program. This initiative focuses on supporting water quality-related projects within the Central Coast Regional Water Quality Control Board’s jurisdiction. The program's core mission aligns with the Rose Foundation's broader goals of fostering environmental health and community well-being, specifically by addressing critical water issues in California's Central Coast. The program primarily targets projects that advance environmental justice and provide water quality benefits to underrepresented communities. This focus aims to address historical inequities and ensure that all communities have access to clean and safe water. The expected outcomes include tangible improvements in water quality, enhanced environmental justice outcomes, and increased resiliency for communities facing water-related challenges. Measurable results will likely involve reductions in pollutant loading, progress toward water quality objectives, and the preservation and restoration of watershed functions. Key priorities and preferred topic areas for this grant include the human right to water, environmental justice capacity building, and understanding the water quality impacts of climate change. The program also emphasizes drought-related water supply resiliency, climate adaptation and mitigation, sustainable drinking water and wastewater treatment, and sustainable groundwater management strategies. Additionally, projects that benefit marine habitats in San Luis Obispo County, reduce pollutant loading to meet Central Coast Basin Plan objectives, restore impaired waterbodies, implement on-farm Best Management Practices to reduce salt and nitrate, and prevent or address Harmful Algal Blooms are highly encouraged. The grant offers two funding tracks: a Large Grant Track for requests up to $200,000 (with most awards between $100,000-$200,000) and a Small Grant Track for requests up to $50,000 (with most awards between $20,000-$50,000). Eligible applicants include 501(c)(3) nonprofit organizations, federally recognized and State Indian tribes, and public agencies with jurisdiction over water resources management. All projects must be conducted within the Central Coast Water Board's Region 3 jurisdiction, encompassing Southern Santa Clara, Santa Cruz, San Benito, Monterey, San Luis Obispo, Santa Barbara, and portions of Ventura, Kern, and San Mateo Counties. The foundation's strategic approach underscores a commitment to community-driven solutions and measurable environmental impact through collaborative partnerships.

This funding opportunity supports innovative research that investigates how aging affects individuals living with HIV, focusing on improving their health outcomes and addressing related challenges.

This grant provides financial support for early-career clinician-scientists to conduct patient-oriented research in pain management, focusing on developing effective strategies to address chronic pain and the opioid crisis.

This funding opportunity supports innovative, interdisciplinary research projects that aim to fill critical knowledge gaps and advance scientific understanding in areas related to kidney, diabetes, and digestive diseases.

This funding opportunity supports students enrolled in dual-degree medical and research training programs, helping them develop into independent physician-scientists through mentored research and clinical training.

This funding opportunity supports clinical trials aimed at developing new therapies for rare neurodegenerative diseases, such as ALS, and is open to a wide range of eligible organizations, including universities and nonprofits.

This funding opportunity supports research initiatives focused on non-communicable diseases related to HIV at institutions in low- and middle-income countries, encouraging innovative projects and collaborations to improve health outcomes for people living with HIV.

This Notice of Funding Opportunity (NOFO) seeks to foster new multi-disciplinary teams to address how HIV Comorbidities and co-infections within the missions of NIDDK and NIAID interact with viral reservoirs, potentially confounding cure strategies aimed at either sustained viral suppression or elimination from the body. These teams will mechanistically interrogate the impact of inflammation, metabolic perturbations, or other pathophysiological processes associated with these comorbidities or co-infections on reservoir dynamics, and/or the interplay of these conditions and co-infections on HIV reservoir biology in ways that are likely to interact with potential cure strategies.

This funding opportunity provides financial support to nonprofit organizations and municipal agencies in New York State to implement community-level strategies that promote healthy eating and physical activity, particularly in underserved areas.

This grant provides funding for early stage investigators to pursue innovative and high-risk research projects involving human participants, without the need for preliminary data.

This funding opportunity provides financial support to U.S.-based organizations, including universities, nonprofits, and businesses, to help outsourcing facilities produce critical medications that are in short supply and vulnerable to fraud.

The purpose of this funding opportunity announcement (FOA) is to fund innovative research that will strengthen and advance minority health and health equity objectives.Areas of interest include:Proposals that focus on advancing equity in clinical trials by supporting efforts to advance diversity in clinical trials, equitable data efforts by increasing data available on diverse groups including, but not limited to, ethnicity, race, age, disability and geography, and equity of voices by increasing understanding of diverse patient perspectives, preferences, and unmet needs.

The purpose of this funding opportunity is to support the research and development necessary to advance non-invasive (e.g., quantitative tomography-based) technologies, including the development of apparatus, methods, study designs, and methods of data analysis, to characterize and compare the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin in vivo. The expectation is that the funded work will produce an accurate, sensitive and reproducible approach that rapidly measures the (relative) amount of drug present in the skin at a series of depths below the skin surface, which can be utilized to monitor the cutaneous pharmacokinetics (PK) of the drug at selected depths (e.g., in the epidermis) by repeated, serial measurements over time. The intent is to support the eventual development of an alternative, scientifically valid, in vivo cutaneous PK-based approach that can be used to efficiently demonstrate the bioequivalence (BE) of topical products.

The purpose of the funding opportunity is to expand and advance FDA's Office of Minority Health and Health Equity (OMHHE) work with stakeholders and partners for education, outreach, and public awareness activities on potential risks from skin lightening products containing hydroquinone and/or mercury.Applicants will research and propose innovative and community-based strategies and activities that have the potential to strengthen the science base for education and public health awareness on the use of and potential risks from over-the-counter (OTC) skin lightening products.

The Green Transportation Capital Grant Program, administered by the Washington State Department of Transportation, aims to fund cost-effective capital projects for transit authorities. Its core mission is to reduce the carbon intensity of Washington's transportation system, aligning with broader climate action efforts supported by the state's Climate Commitment Act (CCA). The CCA's strategic priority is to decrease climate pollution, create jobs, and enhance public health, making this grant a direct mechanism to achieve these goals by investing in sustainable transportation solutions. The primary beneficiaries of this program are transit agencies within Washington state, including various city, county, metropolitan, public, unincorporated, regional, and special purpose district transit systems. The impact goals are centered on transforming public transportation infrastructure to be more environmentally friendly. This includes the electrification of transit vehicle fleets and the development of necessary supporting infrastructure, such as charging and fueling stations, and associated electrical system upgrades. The program prioritizes capital projects that directly contribute to fleet electrification and the transition to zero-emission transportation. Eligible projects encompass the acquisition of battery and fuel cell-operated electric vehicles, modification of facilities for electrification or hydrogen refueling, and the construction of new facilities that primarily support electrified fleets. Additionally, it covers essential upgrades to electrical transmission and distribution systems, in-house staff managing capital construction, and property rights acquisition for these projects. The expected outcomes and measurable results include a significant reduction in carbon emissions from the Washington transportation sector, directly contributing to the state's climate goals. Historically, the program has awarded between $12 million and $50 million per biennium, indicating a substantial investment in achieving these outcomes. The project period for most applications is two years (July 1, 2025 – June 30, 2027), with construction projects potentially extending to four years, allowing for tangible progress in transitioning to green transportation.

Not Available

This funding opportunity provides financial support for new researchers from diverse backgrounds to conduct small-scale health-related studies, helping them advance towards independent research careers.

This Notice of Funding Opportunity (NOFO) invites applications for Diabetes Research Centers (DRCs) that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. The purpose of this Centers program is to bring together basic and clinical investigators to enhance communication, multidisciplinary collaboration, and effectiveness of ongoing research in Diabetes Research Center topic areas. By providing shared access to specialized technical resources (research cores) and supporting a Pilot and Feasibility Program (P and F), DRCs are intended to create an environment that provides the capability for accomplishments greater than those that would be possible by individual research project grant support alone. New Center programs that bring in diverse perspectives, propose unique scientific themes, or provide innovative resources are encouraged. Emphasis will be placed on Center programs that propose enhanced synergies with other NIDDK-funded programs as well as providing a rich mentoring environment for future diabetes researchers. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

The Chautauqua County Tourism Product Development Grant Program, with a deadline of 10/01/2024, offers $10,000 to $100,000 for projects that enhance tourism and recreation opportunities, increase visibility, and promote overnight stays in the county, with a focus on event development, marketing, and attraction enhancement.

The objective of this research proposal is to develop physiologically based pharmacokinetic (PBPK) model-based mechanistic in vitro in vivo correlations (IVIVCs) for two major types of long acting injectables (LAIs) such as crystalline suspensions and polymer-based implants by considering their distinct characteristics. The goal of the project is to develop a bottom-up mechanistic PBPK model for these two LAI categories by accounting for the influence of critical formulation attributes of each LAI drug product type to predict its in vivo release mechanism. The model formulation parameters and relevant physiology should be informed with suitable in vitro and in vivo experiments. A suitable preclinical animal model can be used to validate the PBPK model based IVIVCs for both LAI suspensions and polymer based implants. The use of PBPK modelling provides a unique opportunity to understand how the physicochemical properties of drug molecules/polymer, implant specific properties, critical formulation attributes, and physiology, among other things, influence the in vivo release mechanisms of LAI drug products and their disposition characteristics. Moreover, once developed, a mechanistic PBPK model can help to define the 'safe space' for critical formulation attributes relevant to the reference listed drug (RLD) product, explain sources of PK variability and extrapolate predictions to human subjects by leveraging animal model data and by accounting for species-specific physiological differences.